John Libbey Eurotext

European Journal of Dermatology


Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure Volume 28, numéro 1, January-February 2018


  • Figure 1
Department of Dermatology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

Pembrolizumab is a humanized monoclonal antibody that blocks programmed cell death 1 (PD-1) and results in continuous T-cell activation [1]. However, this T-cell activation is not tumour-specific and causes immune-related adverse events (irAEs) [2]. Here, we report a patient who developed autoimmune interstitial pneumonitis (IP) induced by pembrolizumab as the third-line treatment after nivolumab and ipilimumab failure.A 44-year-old man was admitted to our hospital because of progressive dyspnoea [...]